ACADIA PHARMACEUTICALS INC. Payments to Acquire Debt Securities, Available-for-sale
ACADIA PHARMACEUTICALS INC. (ACAD) reported Payments to Acquire Debt Securities, Available-for-sale of $108.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-05
- ACADIA PHARMACEUTICALS INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $93.44M, a 46.42% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $15.01M, a 90.38% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $157.61M, a 16.10% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $204.55M, a 35.03% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $692.57M, a 37.12% increase from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $505.10M, a 36.52% increase from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $369.99M, a 1.88% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $363.17M, a 26.30% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $93.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $108.45M 10-Q · filed 2026-08-05 | $266.06M derived: sum of 3 quarters · filed 2026-08-05 | $470.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $15.01M 10-Q · filed 2026-05-07 | $172.62M derived: sum of 2 quarters · filed 2026-05-07 | $377.17M derived: sum of 3 quarters · filed 2026-05-07 | $551.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $157.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $362.17M derived: sum of 2 quarters · filed 2026-02-26 | $536.55M derived: sum of 3 quarters · filed 2026-08-05 | $692.57M 10-K · filed 2026-02-26 |
| 2025-09-30 | $204.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $378.94M derived: sum of 2 quarters · filed 2026-08-05 | $534.95M 10-Q · filed 2025-11-06 | $670.71M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $174.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $330.40M 10-Q · filed 2026-08-05 | $466.16M derived: sum of 3 quarters · filed 2026-08-05 | $617.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $156.01M 10-Q · filed 2026-05-07 | $291.77M derived: sum of 2 quarters · filed 2026-05-07 | $443.26M derived: sum of 3 quarters · filed 2026-05-07 | $580.95M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $135.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $287.25M derived: sum of 2 quarters · filed 2026-02-26 | $424.94M derived: sum of 3 quarters · filed 2026-02-26 | $505.10M 10-K · filed 2026-02-26 |
| 2024-09-30 | $151.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $289.18M derived: sum of 2 quarters · filed 2025-11-06 | $369.33M 10-Q · filed 2025-11-06 | $473.44M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $137.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $217.85M 10-Q · filed 2025-08-07 | $321.95M derived: sum of 3 quarters · filed 2026-02-26 | $359.16M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $80.15M 10-Q · filed 2025-05-08 | $184.26M derived: sum of 2 quarters · filed 2026-02-26 | $221.46M derived: sum of 3 quarters · filed 2026-02-26 | $383.25M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $104.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $141.31M derived: sum of 2 quarters · filed 2026-02-26 | $303.09M derived: sum of 3 quarters · filed 2026-02-26 | $369.99M 10-K · filed 2026-02-26 |
| 2023-09-30 | $37.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $198.99M derived: sum of 2 quarters · filed 2024-11-07 | $265.88M 10-Q · filed 2024-11-07 | $359.43M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $161.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $228.68M 10-Q · filed 2024-08-07 | $322.22M derived: sum of 3 quarters · filed 2025-02-27 | $466.47M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $66.89M 10-Q · filed 2024-05-09 | $160.44M derived: sum of 2 quarters · filed 2025-02-27 | $304.69M derived: sum of 3 quarters · filed 2025-02-27 | $430.07M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $93.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $237.80M derived: sum of 2 quarters · filed 2025-02-27 | $363.17M derived: sum of 3 quarters · filed 2025-02-27 | $363.17M 10-K · filed 2025-02-27 |
| 2022-09-30 | $144.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $269.63M derived: sum of 2 quarters · filed 2023-11-03 | $269.63M 10-Q · filed 2023-11-03 | $308.58M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $125.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $125.38M 10-Q · filed 2023-08-03 | $164.33M derived: sum of 3 quarters · filed 2024-02-28 | $415.65M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-08 | $38.95M derived: sum of 2 quarters · filed 2024-02-28 | $290.27M derived: sum of 3 quarters · filed 2024-02-28 | $364.93M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $38.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $290.27M derived: sum of 2 quarters · filed 2024-02-28 | $364.93M derived: sum of 3 quarters · filed 2024-02-28 | $492.80M 10-K · filed 2024-02-28 |
| 2021-09-30 | $251.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $325.98M derived: sum of 2 quarters · filed 2022-11-03 | $453.85M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $74.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $202.53M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $127.86M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $339.91M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $578.63M 10-K · filed 2022-03-01 | |||
| 2011-12-31 | $8.25M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-06 | $14.91M derived: sum of 2 quarters · filed 2012-03-06 | $48.07M 10-K · filed 2012-03-06 | |
| 2011-09-30 | $6.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $39.81M 10-Q · filed 2011-11-09 | ||
| 2011-06-30 | $33.16M 10-Q · filed 2011-08-10 | |||
| 2010-12-31 | $18.21M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-06 | $29.62M derived: sum of 2 quarters · filed 2012-03-06 | $54.67M 10-K · filed 2012-03-06 | |
| 2010-09-30 | $11.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $36.46M 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | $25.06M 10-Q · filed 2011-08-10 | |||
| 2009-12-31 | $50.27M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |